

## CBP-307

**Name:** CBP-307

**Synonyms:** NA


**Indication:** Multiple Sclerosis; Inflammatory bowel disease and Psoriasis

**Company:** Suzhou Connect Biopharmaceuticals

CBP-307 is a novel and selective second generation S1P1 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease and psoriasis. CBP-307 exhibited excellent safety features and potent T cell modulation activity as well as optimal pharmacokinetics and pharmacodynamics profiles, demonstrating the best-in-class potential. CBP-307 is in phase I clinical trials by Suzhou Connect for the treatment of autoimmune diseases.

CBP-307 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.

### CHEMICAL STRUCTURE



### THEORETICAL ANALYSIS

Name: CBP-307

CAS#: Unknown

Chemical Formula: C<sub>24</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>3</sub>

Exact Mass: 423.1958

Molecular Weight: 423.4884

Elemental Analysis: C, 68.07; H, 6.19; F, 4.49; N, 9.92; O, 11.33

**Synonym:** CBP-307; CBP 307; CBP307.

**IUPAC/Chemical Name:** (1s,3s)-3-((2-fluoro-4-(5-(4-isobutylphenyl)-1,2,4-oxadiazol-3-yl)benzyl)amino)cyclobutane-1-carboxylic acid

**InChi Key:** JNFXMFRSTYONCX-GUAVBDGJSA-N

**InChi Code:** InChI=1S/C24H26FN3O3/c1-14(2)9-15-3-5-16(6-4-15)23-27-22(28-31-23)17-7-8-18(21(25)12-17)13-26-20-10-19(11-20)24(29)30/h3-8,12,14,19-20,26H,9-11,13H2,1-2H3,(H,29,30)/t19?,20-

**SMILES Code:** CC(C)CC(C=C1)=CC=C1C2=NC(C3=CC(F)=C(CN[C@@H]4C[C@H](C(O)=O)C4)C=C3)=NO2